Eli Lilly and Company has entered a strategic collaboration to co-develop Nektar Therapeutics’ new immunological therapy NKTR-358.

Having achieved the first human dose in Phase I clinical development in March this year, NKTR-358 can be used to treat a wide range of autoimmune and other chronic inflammatory conditions.

Discovered by Nektar Therapeutics, the treatment is a potential first-in-class resolution therapeutic that can address an underlying immune system imbalance in patients with several autoimmune conditions.

NKTR-358 targets the interleukin (IL-2) receptor complex in the patient’s body to stimulate proliferation of powerful inhibitory immune cells, known as regulatory T-cells.

The treatment is capable of activating these regulatory T-cells to bring the immune system back into balance, thereby resulting into healthy organ function in autoimmune conditions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Nektar president and CEO Howard Robin said: “We are very pleased to enter into this collaboration with Lilly as they have strong expertise in immunology and a successful track record in bringing novel therapies to market.

“Importantly, this agreement enables the broad development of NKTR-358 in multiple autoimmune conditions in order to achieve its full potential as a first-in-class resolution therapeutic.”

Under the deal, Nektar Therapeutics will receive an initial payment of $150m and will be eligible for up to $250m in additional development and regulatory milestones.

"We are very pleased to enter into this collaboration with Lilly as they have strong expertise in immunology and a successful track record in bringing novel therapies to market."

The two companies will be jointly responsible for the manufacturing of NKTR-358, while Nektar will be responsible for completing the Phase I clinical development.

The Phase II development cost will be shared by both companies, with 75% investment from Lilly and the remaining 25% from Nektar Therapeutics.

In addition, Nektar will have the option to participate in Phase III development on an indication-by-indication basis.

Lilly will be responsible for all costs related to global commercialisation, while Nektar will have a provision to co-promote NKTR-358 in the US under certain conditions.


Image: Eli Lilly and Company's global headquarters, in Indianapolis, Indiana, US. Photo: courtesy of Guanaco152003 via Wikipedia.